Selected Publications



Reis ES, Mastellos DC, Ricklin D, Mantovani A, Lambris JD. (2017). Complement in cancer: untangling an intricate relationship. Nature Reviews. Immunology 18: 5-18.

Facciabene A, De Sanctis F, Pierini S, Reis ES, Balint K, Facciponte J, Rueter J, Kagabu M, Magotti P, Lanitis E, DeAngelis RA, Buckanovich RJ, Song WC, Lambris JD, Coukos G. (2017). Local endothelial complement activation reverses endothelial quiescence, enabling t-cell homing, and tumor control during t-cell immunotherapy. Oncoimmunology 6: e1326442.

Evgin L, Ilkow CS, Bourgeois-Daigneault MC, de Souza CT, Stubbert L, Huh MS, Jennings VA, Marguerie M, Acuna SA, Keller BA, Lefebvre C, Falls T, Le Boeuf F, Auer RA, Lambris JD, McCart JA, Stojdl DF, Bell JC. (2016). Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodies. Molecular Therapy Oncolytics 3: 16027.

Evgin L, Acuna SA, Tanese de Souza C, Marguerie M, Lemay CG, Ilkow CS, Findlay CS, Falls T, Parato KA, Hanwell D, Goldstein A, Lopez R, Lafrance S, Breitbach CJ, Kirn D, Atkins H, Auer RC, Thurman JM, Stahl GL, Lambris JD, Bell JC, McCart JA. (2015). Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques. Molecular Therapy 23: 1066-76.

Doerner SK, Reis ES, Leung ES, Ko JS, Heaney JD, Berger NA, Lambris JD, Nadeau JH. (2016). High-fat diet-induced complement activation mediates intestinal inflammation and neoplasia, independent of obesity. Molecular Cancer Research 14: 953-965.

C3 glomerulopathy (C3G)

Mastellos DC, Reis ES, Ricklin D, Smith RJ, Lambris JD. (2017). Complement C3-targeted therapy: replacing long-held assertions with evidence-based discovery. Trends Immunology 38: 383-394.

Zhang Y, Shao D, Ricklin D, Hilkin BM, Nester CM, Lambris JD, Smith RJ. (2015). Compstatin analog Cp40 inhibits complement dysregulation in vitro in C3 glomerulopathy. Immunobiology 220: 993-8.


Hasturk H, Hajishengallis G, Lambris JD, Mastellos DM, Yancopoulou D. (2021). Phase 2a clinical trial of complement C3 inhibitor AMY-101 in adults with periodontal inflammation. J Clin Invest. 131: e152973. Additional Links: Supplemental Data. Video.

Hajishengallis G, Hasturk H, Lambris JD, Contributing authors. (2021). C3-targeted therapy in periodontal disease: moving closer to the clinic. Trends Immunology 42: 856-864.

Balta MG, Papathanasiou E, Blix IJ, Van Dyke TE. (2021). Host Modulation and Treatment of Periodontal Disease. Journal of Dental Research 100: 798-809.

Hajishengallis G, Kajikawa T, Hajishengallis E, Maekawa T, Reis ES, Mastellos DC, Yancopoulou D, Hasturk H, Lambris JD. (2019). Complement-Dependent Mechanisms and Interventions in Periodontal Disease. Frontiers in Immunology 10: 406.

Kajikawa T, Briones RA, Resuello RR, Tuplano JV, Reis ES, Hajishengallis E, Garcia CA, Yancopoulou D, Lambris JD, Hajishengallis G. (2017). Safety and efficacy of the complement inhibitor AMY-101 in a natural model of periodontitis in non-human primates. Molecular Therapy. Methods & Clinical Development 6: 207-215.

Hajishengallis G, Hajishengallis E, Kajikawa T, Wang B, Yancopoulou D. (2016). Complement inhibition in pre-clinical models of periodontitis and prospects for clinical application. Seminars in Immunology 28: 285-91.

Maekawa T, Briones RA, Resuello RR, Tuplano JV, Hajishengallis E, Kajikawa T, Koutsogiannaki S, Garcia CA, Ricklin D, Lambris JD, Hajishengallis G. (2016). Inhibition of pre-existing natural periodontitis in non-human primates by a locally administered peptide inhibitor of complement C3. Journal of Clinical Periodontology 43: 238-49.

Mastellos DC, Ricklin D, Hajishengallis E, Hajishengallis G, Lambris JD. (2016). Complement therapeutics in inflammatory diseases: promising drug candidates for C3-targeted intervention. Molecular Oral Microbiology 31: 3-17.

Maekawa T, Abe T, Hajishengallis E, Hosur KB, DeAngelis RA, Ricklin D, Lambris JD, Hajishengallis G. (2014). Genetic and intervention studies implicating complement C3 as a major target for the treatment of periodontitis. Journal of Immunology 192: 6020-7.

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Mastellos DC, Reis ES, Yancopoulou D, Risitano AM, Lambris JD. (2018). Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria. Seminars in Hematology 55: 167-175.

Lin Z, Schmidt CQ, Koutsogiannaki S, Ricci P, Risitano AM, Lambris JD, Ricklin D. (2015). Complement C3dg-mediated erythrophagocytosis: implications for paroxysmal nocturnal hemoglobinuria. Blood 126: 891-4.

Risitano AM, Ricklin D, Huang Y, Reis ES, Chen H, Ricci P, Lin Z, Pascariello C, Raia M, Sica M, Del Vecchio L, Pane F, Lupu F, Notaro R, Resuello RR, Deangelis RA, Lambris JD. (2014). Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria. Blood 123: 2094-101.

Mastellos DC, Ricklin D, Yancopoulou D, Risitano A, Lambris JD. (2014). Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape. Expert Review of Hematology 7: 583-98.


Skendros P, Germanidis G, Mastellos DC, Antoniadou C, Gavriilidis E, Kalopitas G, Samakidou A, Liontos A, Chrysanthopoulou A, Ntinopoulou M, Kogias D, Karanika I, Smyrlis A, Cepaityte D, Fotiadou I, Zioga N, Mitroulis I, Gatselis NK, Papagoras C, Metallidis S, Milionis H, Dalekos GN, Willems L, Persson B, Manivel VA, Nilsson B, Connolly ES, Iacobelli S, Papadopoulos V, Calado RT, Huber-Lang M, Risitano AM, Yancopoulou D, Ritis K, Lambris JD. (2022). Complement C3 inhibition in severe COVID-19 using compstatin AMY-101. Sci Adv. 8: eabo2341.

Mastellos DC, Pires da Silva BGP, Fonseca BAL, Fonseca NP, Martins MA, Mastaglio S, Ruggeri A, Sironi M, Radermacher P, Chrysanthopoulou A, Skendros P, Ritis K, Manfra I, Iacobelli S, Huber-Lang M, Nilsson B, Yancopoulou D, Connolly S, Garlanda C, Ciceri F, Risitano A, Calado RT, Lambris JD. (2020). Complement C3 vs C5 inhibition in severe COVID-19: early clinical findings reveal differential biological efficacy. Clinical Immunology 220: 108598. Additional Links: Supplement. Commentary. Letter to the Editor.

Skendros P, Mitsios A, Chrysanthopoulou A, Mastellos DC, Metallidis S, Rafailidis P, Ntinopoulou M, Eleni Sertaridou E, Tsironidou V, Tsigalou C, Tektonidou M, Konstantinidis T, Papagoras C, Mitroulis I, Germanidis G, Lambris JD*, Ritis K*. (2020). Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis. The Journal of Clinical Investigation. *Shared supervision. Additional Links: Commentary. E-letter.

Mastaglio S, Ruggeri A, Risitano AM, Angelillo P, Yancopoulou D, Mastellos DC, Huber-Lange M, Piemontese S, Assanelli A, Garlanda C, Lambris JD, Ciceri F. (2020). The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. Clinical Immunology 215: 108450.

Risitano AM, Mastellos DC, Huber-Lang M, Yancopoulou D, Garlanda C, Ciceri F, Lambris JD. (2020). Comment: Complement as a target in COVID-19? Nature Reviews Immunology 20: 343-344.


Compstatins (AMY-101 and other 3rd and 4th generation analogs)

Qu H, Ricklin D, Bai H, Chen H, Reis ES, Maciejewski M, Tzekou A, DeAngelis RA, Resuello RR, Lupu F, Barlow PN, Lambris JD. (2013). New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic properties. Immunobiology 218: 496-505.

Knerr PJ, Tzekou A, Ricklin D, Qu H, Chen H, van der Donk WA, Lambris JD. (2011). Synthesis and activity of thioether-containing analogues of the complement inhibitor compstatin. ACS Chemical Biology 6: 753-60.

Qu H, Magotti P, Ricklin D, Wu EL, Kourtzelis I, Wu YQ, Kaznessis YN, Lambris JD. (2011). Novel analogues of the therapeutic complement inhibitor compstatin with significantly improved affinity and potency. Molecular Immunology 48: 481-9.

Mastellos DC, Yancopoulou D, Kokkinos P, Huber-Lang M, Hajishengallis G, Biglarnia AR, Lupu F, Nilsson B, Risitano AM, Ricklin D, Lambris JD. (2015). Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention. European Journal of Clinical Investigation 45: 423-40.

Berger N, Alayi TD, Resuello RR, Tuplano JV, Reis ES, Lambris JD. (2018). New Analogs of the Complement C3 Inhibitor Compstatin with Increased Solubility and Improved Pharmacokinetic Profile. Journal of Medicinal Chemistry 61: 6153-6162.

For complete of literature from the founder lab on compstatin click here.

Mini-H (AMY-201)

Schmidt CQ, Bai H, Lin Z, Risitano AM, Barlow PN, Ricklin D, Lambris JD. (2013). Rational engineering of a minimized immune inhibitor with unique triple-targeting properties. Journal of Immunology 190: 5712-21.

Xue X, Wu J, Ricklin D, Forneris F, Di Crescenzio P, Schmidt CQ, Granneman J, Sharp TH, Lambris JD, Gros P. (2017). Regulator-dependent mechanisms of C3b processing by factor I allow differentiation of immune responses. Nature Structural & Molecular Biology 24: 643-651.

Harder MJ, Anliker M, Höchsmann B, Simmet T, Huber-Lang M, Schrezenmeier H, Ricklin D, Lambris JD, Barlow PN, Schmidt CQ. (2016). Comparative Analysis of Novel Complement-Targeted Inhibitors, MiniFH, and the Natural Regulators Factor H and Factor H-like Protein 1 Reveal Functional Determinants of Complement Regulation. Journal of Immunology 196: 866-76

Schmidt CQ, Harder MJ, Nichols EM, Hebecker M, Anliker M, Höchsmann B, Simmet T, Csincsi Á, Uzonyi B, Pappworth IY, Ricklin D, Lambris JD, Schrezenmeier H, Józsi M, Marchbank KJ. (2016). Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients. Immunobiology 221: 503-11.


Wu YQ, Qu H, Sfyroera G, Tzekou A, Kay BK, Nilsson B, Nilsson Ekdahl K, Ricklin D*, Lambris JD*. (2011). Protection of nonself surfaces from complement attack by factor h-binding peptides: implications for therapeutic medicine. Journal of Immunology 186: 4269-77.

Nilsson PH, Ekdahl KN, Magnusson PU, Qu H, Iwata H, Ricklin D, Hong J, Lambris JD, Nilsson B, Teramura Y. (2012). Autoregulation of thromboinflammation on biomaterial surfaces by a multicomponent therapeutic coating. Biomaterials 34: 985-94.


Hughes S, Gumas J, Lee R, Romano M, Berger N, Gautam AK, Sfyroera G, Chan AL, Gnanaguru G, Connor KM, Kim BJ, Dunaief JL, Ricklin D, Hajishengallis G, Yancopoulou D, Reis ES, Mastellos DC, Lambris JD. (2020). Prolonged intraocular residence and retinal tissue distribution of a fourth-generation compstatin-based C3 inhibitor in non-human primates. Clinical Immunology 214: 108391. Presented at the Retina Society 2020.

Reis ES, Berger N, Wang X, Koutsogiannaki S, Doot RK, Gumas JT, Foukas PG, Resuello RR, Tuplano JV, Kukis D, Tarantal AF, Young AJ, Kajikawa T, Soulika AM, Mastellos DC, Yancopoulou D, Biglarnia AR, Huber-Lang M, Hajishengallis G, Nilsson B, Lambris JD. (2018). Safety profile after prolonged C3 inhibition. Clinical Immunology 197: 96-106.

Ricklin D, Mastellos DC, Reis ES, Lambris JD. (2017). The renaissance of complement therapeutics. Nature Reviews. Nephrology 14: 26-47.

Mastellos DC, Reis ES, Yancopoulou D, Hajishengallis G, Ricklin D, Lambris JD. (2016). From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage. Immunobiology 221: 1046-57.

Reis ES, Mastellos DC, Yancopoulou D, Risitano AM, Ricklin D, Lambris JD. (2015). Applying complement therapeutics to rare diseases. Clinical Immunology 161: 225-240.

Reis ES, DeAngelis RA, Chen H, Resuello RR, Ricklin D, Lambris JD. (2015). Therapeutic C3 inhibitor Cp40 abrogates complement activation induced by modern hemodialysis filters. Immunobiology 220: 476-82.

Lindorfer MA, Cook EM, Reis ES, Ricklin D, Risitano AM, Lambris JD, Taylor RP. (2016). Compstatin Cp40 blocks hematin-mediated deposition of C3b fragments on erythrocytes: Implications for treatment of malarial anemia. Clinical immunology 171: 32-35.

Gravastrand C, Hamad S, Fure H, Steinkjer B, Ryan L, Oberholzer J, Lambris JD, Lacík I, Mollnes TE, Espevik T, Brekke OL, Rokstad AM. (2017). Alginate microbeads are coagulation compatible, while alginate microcapsules activate coagulation secondary to complement or directly through FXII. Acta Biomaterialia 58: 158-167.

Wolf-Grosse S, Rokstad AM, Ali S, Lambris JD, Mollnes TE, Nilsen AM, Stenvik J. (2017). Iron oxide nanoparticles induce cytokine secretion in a complement-dependent manner in a human whole blood model. International Journal of Nanomedicine 12: 3927-3940.

Wang J, Wang L, Xiang Y, Ricklin D, Lambris JD, Chen G. (2015). Using an in vitro xenoantibody-mediated complement-dependent cytotoxicity model to evaluate the complement inhibitory activity of the peptidic C3 inhibitor Cp40. Clinical immunology 162: 37-44.